by Clinical Neuropsychologist Online | Thursday, September 24, 2026 | Dementia
Abstract INTRODUCTION The adiposity–cognition relationship in aging is controversial. This study aimed to assess its sex- and age-specific associations with Alzheimer’s disease (AD) pathology using multimodal biomarkers. METHODS In two longitudinal cohorts (Hubei...
by Clinical Neuropsychologist Online | Thursday, September 24, 2026 | Dementia
Abstract INTRODUCTION Aspirin is not recommended for dementia prevention due to limited benefit. We investigated whether genetic subgroups may benefit. METHODS In the ASPirin in Reducing Events in the Elderly (ASPREE) trial (n = 13,541), we screened 5182 polygenic...
by Clinical Neuropsychologist Online | Thursday, September 24, 2026 | Dementia
Abstract INTRODUCTION Although the ABI3 S209F variant is a recognized genetic risk for Alzheimer’s disease (AD), its pathogenic mechanism remains elusive. METHODS Using AD mouse models (amyloid precursor protein/presenilin 1 [APP/PS1] transgenic mice, 5×familial...
by Clinical Neuropsychologist Online | Thursday, September 24, 2026 | Dementia
Abstract INTRODUCTION Epigenome-wide association studies implicate DNA methylation in Alzheimer’s disease (AD) pathology. Although recent studies identified epigenetic signatures within non-neuronal cell types in disease risk, the role of the methylome in glial...
by Clinical Neuropsychologist Online | Thursday, September 24, 2026 | Dementia
Abstract INTRODUCTION Although Alzheimer’s disease (AD) is prevalent in individuals with chronic kidney disease (CKD), the mechanistic link remains unclear. We assessed the impact of CKD transcriptional risk on AD endophenotypes. METHODS We calculated the CKD...
